RxDoctor Payments Data

Michelle Hernandez Guzman

Internal Medicine · Roslyn Heights, NYNPI 1386179521

Payments from drug & device makers

$3,305in general payments, 2019–2025

Across 120 payments — averaging $27.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Exact Sciences$347
  • GSK$310
  • AbbVie$170
  • Pfizer$149
  • Esperion Therapeutics, Inc.$125
  • plus $568 from 11 others

What the payments were for

  • Food & beverage$3,305100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,305 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$74,110
Medicare patients
230
Services billed
1,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$49,870
EliquisApixaban23$9,687
Mesalamine22$8,488
MotegrityPrucalopride Succinate15$8,011
BelsomraSuvorexant15$6,709
VascepaIcosapent Ethyl11$6,628
Dextroamphetamine Sulfate ErDextroamphetamine Sulfate11$5,537
SynthroidLevothyroxine Sodium73$4,748
Dexlansoprazole DrDexlansoprazole25$3,900
Atorvastatin Calcium186$1,929
Levothyroxine Sodium103$1,843
Rosuvastatin Calcium142$1,658
Azelastine Hcl53$1,025
Losartan Potassium68$959
Zolpidem Tartrate104$932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,636$49,87046 claims
PfizerEliquis$149$9,68723 claims
MerckBelsomra$21$6,70915 claims
AbbVieSynthroid$170$4,74873 claims
Almatica Pharma LLCSertraline Hcl$18$46740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Roslyn Heights

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →